Ir a las Transacciones
Salud

Alcidion (ASX:ALC) has acquired ExtraMed

Alcidion (ASX:ALC) has acquired ExtraMed Ltd., a UK provider of patient flow management software that helps address key pain-points for hospital administrative staff.

Alcidion is transforming healthcare with smart, intuitive and complementary software products and services that create a unique offering in the global healthcare market. It offers solutions that support interoperability, allow communication and task management, and deliver clinical decision support at the point-of-care to improve patient systems. Alcidion has delivered strong organic growth in FY20 (with solid revenue up 33% as of Q3). The acquisition of ExtraMed will further accelerate this growth profile. This will add nine NHS trusts (six being new to Alcidion), expanding its NHS presence to 27 trusts or ~19% of target Acute NHS market, with upside revenue potential on cross-sell opportunities for Miya (its flagship product).

ExtraMed is a long-standing UK market leader in patient flow and has a 20-year track record. It specializes in providing NHS trusts with software that helps frontline staff make informed decisions based on real-time visibility of patient flow.

Oaklins’ team in Australia acted as corporate advisor to the buyer in this transaction.

Partes

Contáctese con el equipo de la transacción

Scott McInnes

Director Ejecutivo
Melbourne, Australia
Oaklins Henslow

Sebastian Bell

Director
Sydney, Australia
Oaklins Henslow

Transacciones relacionadas

Medicija has acquired Saulės Šeimos Medicinos Centras
Salud

Medicija has acquired Saulės Šeimos Medicinos Centras

Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.

Aprenda más
Quimpharma has completed the divestiture of a product portfolio to Megalabs
Salud

Quimpharma has completed the divestiture of a product portfolio to Megalabs

Quimpharma has completed the divestiture of a product portfolio to Megalabs México.

Aprenda más
IXICO has completed a fundraising
Salud

IXICO has completed a fundraising

IXICO plc, a specialist in AI-driven neuroimaging analytics, has completed a US$13.5 million gross capital raise. The funds will be used to support the company’s tech bio strategy, which will see IXICO partner its platform to maximize its potential.

Aprenda más